Citations

Clear

1422 citation(s) found for "White, JB".

NCOG-12. COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402
Won, Minhee , Cairncross, J. Gregory , Buckner, Jan C. , Fink, Karen, Bahary, Jean-Paul , Hartford, Alan C. , Souhami, Luís, Nguyen, Timothy K., Cescon, Terrence P., Pu, Anthony T. , Roa, Wilson , Polley, M.Y., Donovan, Laura, IWAMOTO, FABIO MASSAITI , Mishra, Mark V. , Barani, Igor J. , Huang, Jiayi , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi154-vi154

10.1093/neuonc/noab196.603 Get It

Abstract BACKGROUND PCV+RT substantially prolongs survival in AO patients, but long-term CF and QOL implications are unclear. We compared CF and QOL by treatment arm in RTOG 9402 participants and evaluated the impact that baseline characteristics had on CF, QOL, and survival. METHODS CF and QOL were evaluated using the Mini Mental State Exam (MMSE) and Brain-Quality of Life (B-QOL) scale at baseline and annually. Scores were analyzed between treatment arms at each time point for patients with ≥ 10 years of follow-up data. Shared parameter models evaluated MMSE and B-QOL scores and survival for all patients. RESULTS 42/148 (28.4%) participants in PCV+RT and 20/143 (14%) in RT alone arms survived ≥ 10 years. 35/42 and 39/42 (PCV+RT) and 18/20 and 17/20 (RT) participants completed baseline B-QOL and MMSE assessments, respectively. B-QOL scores did not differ between treatment groups at any time-point. Among 16 patients (10 PCV+RT, 6 RT) who completed year 10 MMSE evaluations, mean MMSE score at 10 years was higher in the RT arm (29.83 [95% CI 22.1, 30.0] vs. 26.50 [95% CI 29.4, 30.0], P= 0.04). Change in MMSE and B-QOL scores from baseline did not differ significantly between treatment groups at any time. In shared parameter models including all patients with baseline assessments, MMSE and B-QOL scores decreased over time (MMSE P= 0.0189, B-QOL P= 0.0005), but this did not differ by treatment group (MMSE P= 0.5727, B-QOL P= 0.3592). Younger age and higher KPS predicted better scores (MMSE P < 0.0001, P = 0.0002; B-QOL P = 0.0043, P = 0.0007). PCV+RT predicted better survival in both models. CONCLUSIONS PCV+RT improves survival in AO. Shared parameter models show decrease in MMSE and B-QOL over time. However, relative to RT alone, the addition of PCV did not impact change in CF and QOL over time.
CSIG-08. ABT-414 RESISTANT GBM TUMORS HARBOR THE TEK S466I MUTATION AND EXHIBIT INCREASED STEMNESS
Blomquist, Mylan, Sereduk, Christopher, Rabichow, Benjamin E. , Miller, Aunay , Marin, Bianca M. , Lasorella, Anna , Marin, Bianca M , Noviello, Teresa , D’Angelo, Fulvio , Sereduk, Chris , White, Forest M. , Sarkaria, Jann N. , Iavarone, Antonio , Ceccarelli, Michele , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi34-vi35

10.1093/neuonc/noab196.134 Get It

Abstract Glioblastoma (GBM), the most common primary brain tumor in adults, remains uniformly fatal due to the lack of effective targeted therapies for this aggressive malignancy. Genomic amplification of epidermal growth factor receptor (EGFR) occurs in 40-60% of primary GBM. Half of all EGFR-amplified cases of GBM also harbor EGFRvIII, a constitutively active, truncated variant of EGFR. The incidence of EGFR alterations in GBM makes inhibition of EGFR/EGFRvIII an attractive therapeutic approach. Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprised of ABT-806, a mAB against EGFR, and a cytotoxic payload (monomethyl auristatin F). ABT-414 therapy initially showed promising results as an EGFRvIII therapy in vivo and in vitro; however, ABT414 failed to provide a survival benefit in phase I/II clinical trials, potentially due to therapeutic resistance. In this study, we seek to investigate the mechanisms of resistance to ABT-414 by performing whole exome, transcriptome and single cell RNA seq on ABT-414 resistant GBM PDX tumors. Our data showed an enrichment of mutations unique to the ABT-414 resistant tumors, including a point mutation (S466I) in TEK/TIE2 transmembrane angiopoietin receptor. In vitro expression of TEK S466I in GBM cells showed an increase in activation of ERK and STAT3 and increased TEK/TIE2 immunoprecipitation with EGFR compared to the wild-type TEK receptor. Furthermore, gene ontology analysis reveals that ABT-414-treated flank tumors exhibit increased activation of extracellular matrix organization and CNS developmental processes compared to flank tumors in the control treatment groups. ABT-414-treated tumors also demonstrate increased expression of inhibitor of differentiation (ID)1 and ID3, associated with stem-like phenotype in glioblastoma. Taken together, our data indicate that resistance to ABT-414 is mediated by both de novo mutations not detected in the parent tumor and adaptive dysregulation of pathways which may lead to dedifferentiation and therapeutic resistance.
A Policy Framework to Support Shared Decision-Making through the Use of Person-Generated Health Data
Edmunds, Margo, McGraw, Deven , Priest, Elisa L. , Smith, Jeffery, Kemp, Eagan, Campos, Hugo , Petersen, Carolyn

Mayo Clinic

ACI Open | November 16, 2021 | Volume: 05 | Issue: 02 | Pages: e104-e115

10.1055/s-0041-1736632 Get It

Abstract Background Individuals increasingly want to access, contribute to, and share their personal health information to improve outcomes, such as through shared decision-making (SDM) with their care teams. Health systems' growing capacity to use person-generated health data (PGHD) expands the opportunities for SDM. However, SDM not only lacks organizational and information infrastructure support but also is actively undermined, despite public interest in it. Objectives This work sought to identify challenges to individual–clinician SDM and policy changes needed to mitigate barriers to SDM. Methods Two multi-stakeholder group of consumers, patients, caregivers; health services researchers; and experts in health policy, informatics, social media, and user experience used a consensus process based on Bardach's policy analysis framework to identify barriers to SDM and develop recommendations to reduce these barriers. Results Technical, legal, organizational, cultural, and logistical obstacles make data sharing difficult, thereby undermining use of PGHD and realization of SDM. Stronger privacy, security, and ethical protections, including informed consent; promoting better consumer access to their data; and easier donation of personal data for research are the most crucial policy changes needed to facilitate an environment that supports SDM. Conclusion Data protection policy lags far behind the technical capacity for third parties to share and reuse electronic information without appropriate permissions, while individuals' right to access their own health information is often restricted unnecessarily, poorly understood, and poorly communicated. Sharing of personal information in a private, secure environment in which data are shared only with individuals' knowledge and consent can be achieved through policy changes.
Connective Tissue Disease Patients Maintain Greater Distraction During Growth Friendly Surgery
Marrache, Majd , Suresh, Krishna V. , White, Klane K. , Larson, A. Noelle , Sponseller, Paul D.

Mayo Clinic

Journal of Pediatric Orthopaedics | November 14, 2021 | Volume: 42 | Issue: 2 | Pages: e188-e191

10.1097/bpo.0000000000002003 | PMID 34995261 Get It

Study Design: Multicenter retrospective study. Background: Recent studies have demonstrated diminishing returns in patients with early onset scoliosis (EOS) undergoing repeated lengthening of growing rods. Little is known about whether this same phenomenon occurs in patients with lax connective tissue disease (CTD). The primary purpose of this study is to investigate whether EOS patients with connective tissue laxity disorders have diminishing returns during growth friendly surgery. Methods: CTD EOS patients below 10 years old, underwent growth friendly spine surgery with distal anchors and at least 1 proximal spine anchor, and had minimum follow-up of 5 years were included in this study. Coronal T1-S1 height at preindex surgery, postindex, and every available lengthening was assessed. Mean coronal height change during early set distractions and late set distractions were calculated for the cohort. To account for varying distraction intervals, we normalized the distractions by the time interval. The outcome parameter was T1-S1 height gain, mm/year. Results: Twenty-one CTD patients were included in this study. Total coronal height (T1-S1) was 26.7MHCcm before index, 32.2 cm at D1-D3, 34.7 cm at D4-D6, and 36.7 cm at D7-L10. There were no significant differences in coronal height gains between early and late distractions (P=0.70). Moreover, when normalized for time, there was no significant difference in net gain per year at different lengthening time points for the CTD group, P=0.59. Conclusion: There is no evidence of diminishing returns in coronal T1-S1 height gain in patients with EOS in the setting of CTD. Level of Evidence: Level III.
Comparison of Bleeding Profiles of Sugammadex and Neostigmine in Orthotopic Liver Transplantation
Liang, Hong , White, Launia J. , Chadha, Ryan , Renew, J. Ross

Mayo Clinic

No container title available | October 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163491381.11148574/v1 Get It

In the era of “fast-track’ liver transplantation (LT), neuromuscular blockade (NMB) antagonists such as neostigmine or sugammadex are used to achieve the restoration of neuromuscular function. While sugammadex reverses NMB faster than neostigmine, it has been shown to prolong prothrombin time (PT) and activated thromboplastin time (aPTT). However, this agent’s impact on coagulation during LT is not understood. We compare bleeding risk associated with sugammadex versus neostigmine during liver transplantation. This is a single-center, retrospective review of LT patients who received NMB antagonists intraoperatively between 01/01/2015 to 05/31/2018 at Mayo Clinic in Florida. The primary outcomes were postoperative day (POD) 0-1 bleeding events and POD 0 values of aPTT and INR. Total 241 patients were included, with 135 patients in the neostigmine group (NG) and 106 in the sugammadex group (SG). POD 0-1 postoperative bleeding requiring transfusion occurred in 20% of NG versus 10.4% in SG. POD 0-1 re-operation for bleeding occurred in 1.5% in NG vs. 0% in SG. POD 0 mean INR was 2.0±0.4 in both groups. POD 0 mean aPTT was 45.5±7.9 in NG vs. 49.3±9.0 in SG. Our retrospective study suggests that sugammadex is not associated with an increased risk of bleeding compared to neostigmine use.
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Mahil, Satveer K. , Dand, Nick , Yiu, Zenas Z N , Zhang, Xian , Strangfeld, Anja , Mateus, Elsa F , Lawson‐Tovey, Saskia , Cuomo, Giovanna , Caprioli, Marta , Cruz-Machado, Ana Rita , Pereira, Ana Carolina Mazeda, Hasseli, Rebecca , Lorenz, Hanns‐Martin , Hoyer, Bimba F. , Trupin, Laura , Rush, Stephanie, Schmajuk, Gabriela , Jacobsohn, Lindsay, Seet, Andrea M. , Emadi, Samar Al, Wise, Leanna , Gilbert, Emily, Valenzuela-Almada, Maria O , Hsu, Tiffany , Sparks, Jeffrey A. , Xavier, Ricardo Machado , Flipo, René‐Marc , Cantagrel, A., Wallace, Zachary S. , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Hausmann, Jonathan S. , Sufka, Paul , Machado, Pedro , Barker, Jonathan N., Smith, Catherine , Coker, Bola , Gisondi, Paolo, Jullien, D., Lambert, Jo, McAteer, Helen , Meynell, Freya, Moorhead, Lucy, Naldi, Luigi, Reynolds, Nick J. , Spuls, Phyllis, Vincent, Alexandra , Waweru, H, Reinisch, Walter , Rahier, Jean‐François , Lewis, James D. , Steinwurz, Flávio , Kissous-Hunt, Michele, Modesto, Irene , Konings, Marishka, Dahou, Brahim, Gómez, Gimena, Roberts, Karen , Báez, Roberto Miguel , Coello, Vanessa Viviana Castro , Salinas, María Jezabel Haye , Maldonado, F., Reyes, Alvaro A., Alle, Gelsomina , Tanten, Romina , Ficco, Hernán Maldonado , Tissera, Yohana , Pisoni, Cecilia , Paula, Alba, Albiero, Juan Alejandro, Schmid, María Marcela, Cosatti, Micaela , Gamba, María Julieta , Leandro, Carlevaris, Cusa, María Alejandra, Germán, Noelia, Bellomio, Verónica , Takashima, Lorena , Pera, Mariana , Elkin, M. S. Gálvez , Medina, María Alejandra , Savio, V. , Tessel, Romina Rojas, Alamino, Rodolfo Pérez, Werner, Marina Laura, Ornella, Sofía , Casalla, Luciana, Vega, María Celina De la , Severina, María de los Ángeles , Lucero, Luciana González , Romeo, Cecilia, Barbich, Tatiana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla , Conti, Silvana, Lázaro, María Alicia, Gil, Gustavo Fabián Rodriguez, Risueño, Fabián, Quaglia, María Isabel, Scafati, Julia , Cuchiaro, Natalia Lili, Rebak, J., Pineda, Susana , Calvo, María Elena, Picco, Eugenia, Yanzi, Josefina Gallino , Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana , Porta, Sabrina , Herscovich, Natalia , Zamora, José Luis Velasco , Kisluk, Boris, Menescardi, Maria Sol Castaños, Gallo, Rosana, Maldini, Carla , Goizueta, Cecilia, Fernandez, Sabrina Solange de la Vega, Aeschlimann, Carolina, Subils, Gisela, Piette, Y, Devinck, Mieke , Maeyaert, Bea, Ribeiro, Francinne Machado , Ribeiro, Sandra Lúcia Euzébio , Trubert, Anne-Marie Chassin, Dong, Lingli , Cajas, Lui, Anić, Branimir, Čulo, Melanie-Ivana , Pavelic, Tea Ahel, Stranski, Kristina Kovacevic, Karanović, Boris , Píchová, Marta, Vassilopoulos, Dimitrios, Melgar, Gabriela Maria Guzman, Király, Márta , Vojdanian, Mahdi, Balbir‐Gurman, Alexandra , Abutiban, Fatemah , Buliņa, Inita , Bukauskienė, Loreta, Montiel, Beatriz E Zazueta, Ortiz, Angel Alejandro Castillo , Tehozol, Erick Adrian Zamora , Rosete, Diana Cervántes, Nares, Eduardo Martín, Reyna, Tatiana S Rodriguez, Gabayet, Marina Rull, Rodríguez, Deshiré Alpízar, Irazoque, Fedra, Jimenez, Xochitl, Bon, Lenny Geurts van, Zijlstra, T. R., Hoekstra, Monique , Adhoubi, Nasra Al , Salim, Babur , Giraldo, Enrique, Salinas, Ariel, Gil, Manuel Ugarte, Flood, Rachael , Felea, Ioana , Filipescu, Ileana, Rednic, Simona , Tamas, Maria Magdelena, Mlynáriková, Vanda , Skamlova, Martina, Žlnay, Martin, Mičeková, Dagmar, Cápová, L, Šteňová, Emὄke , Raffayová, Helena , Belakova, Gabriela, Straková, Eva , Senčarová, Marieta, Žlnayová, Soňa, Sabová, Anna, Spišáková, Daniela, Oetterová, Mária, Lukáčová, Oľga, Bakošová, Martina, Hočevar, Alojzija , Rubio, N. De la Torre , Sancho, Juan José Alegre , Coro, Montserrat Corteguera, García, Juan Carlos Cobeta , Martin, Maria Carmen Torres, Campos, José Luis Michi , Gómez‐Puerta, José A. , Yardimci, Gozd Kubra, İçaçan, Ozan Cemal , Çelik, Selda , Vasylets, Viktoriia, Vandevelde, Claire , Dunt, Sasha, Leeder, Jane, MacPhie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O’Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer , Warner, Elizabeth, Pilcher, James, Patel, Samir J. , Nikiphorou, Elena , Chadwick, Laura , Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah , Jatwani, Shraddha , Baig, Sara , Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Pfeifer, Emily, Skemp, Archibald, Wolff, Anne , Cepeda, Eduardo, Todd, Derrick J. , Hare, Denise, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline H. , Daver, Nicole, Harvey, Melissa , Kramer, Neil , Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Davis, William E. , Quinet, Robert, Scopelitis, Evangeline, Toribio, Karen Toribio, Detiege, Tameka Webb, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Zell, JoAnn, Dao, Kathryn H., Ezzati, Fatemeh, Parks, Deborah, Karp, David R. , Quiceno, Guillermo Andrés, Gilbert, Emily L , Sparks, Jeffrey A , Grainger, Rebecca , Hoyer, Bimba F , Wise, Leanna M , Lawson-Tovey, Saskia , Machado, Pedro M , Hausmann, Jonathan S , Hasseli, Rebecca , Xavier, Ricardo M , Hsu, Tiffany Y-T , Strangfeld, Anja , Mateus, Elsa F , Zamora Tehozol, Erick Adrian , Gomez-Puerta, Jose A , Izadi, Zara , Brenner, Erica J. , Yates, Mark , Ungaro, Ryan C. , Agrawal, Manasi , Colombel, Jean‐Frédéric , Gianfrancesco, Milena A , Hyrich, Kimme L , Carmona, Loreto , Klingberg, Eva , Mazeda, Carolina , Pfeil, Alexander , Katz, Patricia , Duarte‐García, Alí , Isnardi, Carolina A , Quintana, Rosana M , Soriano, Enrique Roberto , D'Silva, Kristin M , Patel, Naomi J , Marques, Cláudia Diniz Lopes , Kakehasi, Adriana María , Claudepierre, Pascal , Goupille, Philippe , Liew, Jean W. , Sirotich, Emily , Robinson, Philip C. , Griffiths, Christopher E.M. , Barker, Jonathan N., Yazdany, Jinoos , Kappelman, Michael D. , Bachelez, Hervé , Capon, Francesca , Cruz, Claudia de la , Mason, Kayleigh J. , Meglio, Paola Di , Gelfand, Joel M. , Gisondi, Paolo , Iversen, Lars , Langan, Sinéad , Puig, L. , Torres, Tiago , Tsakok, Teresa , Warren, Richard Bruce , Ng, Siew C. , Gearry, Richard B. , Reinisch, Walter , Lewis, James D , Kaplan, Gilaad G. , Maldonado, Federico N, Nieto, Romina , Gobbi, Carla Andrea , Cogo, Karina, García, Mercedes , Moyano, Sebastián , Bertoli, Ana María , Martiré, María Victoria , Rath, Eva, Piette, Yves, Pinheiro, Marcelo M. , Ibañez, Sebastián , Barešić, Marko , Vencovský, Jiří , Filková, Mária , Hamoud, Hesham Salah , So, Ho , Zepa, Jūlija , Vega‐Morales, David , Reyna, Tatiana Sofía Rodríguez, Nowakowski, Jarosław , Conway, Richard , McCarthy, Géraldine , Filipescu, I., Groseanu, Laura , Macejová, Želmíra , Strakova, Eva, Campos, Jose, Akar, Servet , Yeoh, Su‐Ann , Morgan, Jennifer , Wilson, Jeffrey, Wolff, Anne, Hare, Denise, Calabrese, Cassandra M. , Adams, Christopher, Khosroshahi, Arezou , Ruderman, Eric , Jayatilleke, Arundathi , Bays, Alison , Parks, Deborah

Mayo Clinic

JAMA Network Open | October 20, 2021 | Volume: 4 | Issue: 10 | Pages: e2129639

10.1001/jamanetworkopen.2021.29639 | PMID 34661663 Get It

Sorbitol Is a Severity Biomarker for PMM2‐CDG with Therapeutic Implications
Ligezka, Anna N. , Radenkovic, Silvia , Saraswat, Mayank , Garapati, Kishore , Ranatunga, Wasantha , Yanaihara, Hitoshi, Preston, Graeme , Brucker, William , McGovern, Renee M., Cassiman, David , Johnsen, Christin , Lam, Christina , Edmondson, Andrew C. , Raymond, Kimiyo , Oglesbee, Devin , Pandey, Akhilesh , Reid, Joel M. , Muthusamy, Karthik , Morava, Eva , Pandey, Akhilesh , Oglesbee, Devin , Edmondson, Andrew C , Garapati, Kishore , Krzyściak, Wirginia , Muthusamy, Karthik , Mercimek‐Andrews, Saadet , Larson, Austin , Ghesquière, Bart , Witters, Peter , Perlstein, Ethan , Kozicz, Tamás , Morava, Éva

Mayo Clinic

Annals of Neurology | October 20, 2021 | Volume: 90 | Issue: 6 | Pages: 887-900

10.1002/ana.26245 | PMID 34652821 Get It

ObjectiveEpalrestat, an aldose reductase inhibitor increases phosphomannomutase (PMM) enzyme activity in a PMM2‐congenital disorders of glycosylation (CDG) worm model. Epalrestat also decreases sorbitol level in diabetic neuropathy. We evaluated the genetic, biochemical, and clinical characteristics, including the Nijmegen Progression CDG Rating Scale (NPCRS), urine polyol levels and fibroblast glycoproteomics in patients with PMM2‐CDG.MethodsWe performed PMM enzyme measurements, multiplexed proteomics, and glycoproteomics in PMM2‐deficient fibroblasts before and after epalrestat treatment. Safety and efficacy of 0.8 mg/kg/day oral epalrestat were studied in a child with PMM2‐CDG for 12 months.ResultsPMM enzyme activity increased post‐epalrestat treatment. Compared with controls, 24% of glycopeptides had reduced abundance in PMM2‐deficient fibroblasts, 46% of which improved upon treatment. Total protein N‐glycosylation improved upon epalrestat treatment bringing overall glycosylation toward the control fibroblasts’ glycosylation profile. Sorbitol levels were increased in the urine of 74% of patients with PMM2‐CDG and correlated with the presence of peripheral neuropathy, and CDG severity rating scale. In the child with PMM2‐CDG on epalrestat treatment, ataxia scores improved together with significant growth improvement. Urinary sorbitol levels nearly normalized in 3 months and blood transferrin glycosylation normalized in 6 months.InterpretationEpalrestat improved PMM enzyme activity, N‐glycosylation, and glycosylation biomarkers in vitro. Leveraging cellular glycoproteome assessment, we provided a systems‐level view of treatment efficacy and discovered potential novel biosignatures of therapy response. Epalrestat was well‐tolerated and led to significant clinical improvements in the first pediatric patient with PMM2‐CDG treated with epalrestat. We also propose urinary sorbitol as a novel biomarker for disease severity and treatment response in future clinical trials in PMM2‐CDG. ANN NEUROL 20219999:n/a–n/a
Orthopaedic Foot and Ankle Surgery Fellowship Directors Are Typically White Men in Their Early 50s With Strong Achievements in Research
Elahi, Muhammad Ali , Makovicka, Justin L. , Brinkman, Joseph C. , Doan, Matthew K. , Hassebrock, Jeffrey D. , Moore, M. Lane , Pollock, Jordan Riley , Patel, Karan A.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | October 12, 2021 | Volume: 3 | Issue: 6 | Pages: No page available

10.1016/j.asmr.2021.07.018 | PMID 34977614 Get It

Purpose To determine the objective characteristics of orthopaedic foot and ankle fellowship directors (FDs) by concentrating on the demographic characteristics, academic background, institutional history, research experience, and professional affiliations of these leaders. Methods Data for each FD were collected by searching institutional biographies, personal websites, or publicly available curricula vitae. Data collection included the following variables: age, sex, race/ethnicity, previous training institutions, residency and fellowship graduation years, advanced degrees, military affiliation, institutional loyalty, year hired, FD career timeline, total number of publications, total number of citations, and h ‐index. Results Of the 47 FDs, 44 (93.6%) were men and 3 (6.4%) were women. The mean age was 50.8 ± 9.4 years. Most orthopaedic foot and ankle FDs were white (n = 42, 89.4%), followed by Asian (n = 4, 8.5%) and black or African American (n = 1, 2.1%). The mean Scopus h ‐index, total number of publications, and total number of citations for all foot and ankle FDs were 13.3 ± 9.5, 47.5 ± 45.8, and 898.1 ± 1,040.3, respectively. Among all foot and ankle FDs, the mean tenure in the FD position was 5.8 ± 4.6 years. Conclusions Orthopaedic foot and ankle FDs are primarily white men in their 50s, with minimal female and minority representations. These FDs are distinguished by their high level of research productivity. Additionally, orthopaedic foot and ankle training backgrounds seem to play an important role, given that most of the appointed FDs trained in only a few select programs. Clinical Relevance This study outlines some of the most important characteristics among foot and ankle FDs and identifies important disparities within this population of leaders that may have detrimental effects on the field.
Impact of Peripheral Microvascular Endothelial Dysfunction on White Matter Hyperintensity
Toya, Takumi , Sara, Jaskanwal Deep Singh , Scharf, Eugene , Ahmad, Ali , Nardi, Valentina , Ӧzcan, Ilke , Lerman, Lilach O. , Lerman, Amir , Sara, Jaskanwal D, Scharf, Eugene L , Ozcan, Ilke , Lerman, Amir , Toya, Takumi , Nardi, Valentina

Mayo Clinic

Journal of the American Heart Association | October 8, 2021 | Volume: 10 | Issue: 20 | Pages: No page available

10.1161/jaha.121.021066 | PMID 34622674 Get It

Background White matter hyperintensity (WMH), characterized by hyperintensities on T2‐weighted fluid‐attenuated inversion recovery brain magnetic resonance imaging, has been linked to an increased risk of ischemic stroke (IS). Endothelial dysfunction is an indicator of vascular dysfunction, predicting the risk of IS. This study aimed to investigate the association between endothelial dysfunction and regional WMH, and its impact on future risk of IS. Methods and Results We enrolled 219 patients (mean age, 53.1±14.1 years; 34.7% men) who underwent peripheral endothelial function assessment using reactive hyperemia peripheral arterial tonometry and brain magnetic resonance imaging without any history of IS. Volumetric WMH segmentation was automatically extrapolated using a validated automated digital tool. Total and juxtacortical WMH volume/intracranial volume (%) increased with aging and became more prominent in patients aged >50 years (n=131) than those aged ≤50 years (n=88) (total WMH: ≤50 years, Pearson r =0.24, P =0.03; >50 years, Pearson r =0.62, P <0.0001; juxtacortical WMH: ≤50 years, Pearson r =0.09, P =0.40; >50 years, Pearson r =0.55, P <0.0001). Reactive hyperemia peripheral arterial tonometry index was negatively associated with total and juxtacortical WMH volume/intracranial volume (%) in patients aged >50 years after adjustment for other covariates (reactive hyperemia peripheral arterial tonometry index, standardized β coefficient −0.17, P =0.04). Juxtacortical WMH volume/intracranial volume (%) was associated with an increased risk of IS during median follow‐up of 6.5 years (hazard ratio, 1.47; 95% CI, 1.05–1.92; P =0.03). Conclusions Peripheral endothelial dysfunction is associated with an increased volume of juxtacortical WMH in patients aged >50 years, which is a potential marker to predict future risk of IS.
Tracking Blood Pressure Control Performance and Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control Laboratory
Cooper‐DeHoff, Rhonda M. , Fontil, Valy, Carton, Thomas, Chamberlain, Alanna M. , Todd, Jonathan, O’Brien, Emily C., Shaw, Kathryn M., Smith, Myra, Choi, Sujung, Nilles, Ester K., Ford, Daniel, Tecson, Kristen M. , Dennar, Princess E., Wu, Shenghui, McClay, James C. , Azar, Kristen , Singh, Rajbir, Modrow, Madelaine Faulkner, Shay, Christina M., Wozniak, Gregory, Pletcher, Mark J. , Nilles, Ester Kim , Modrow, Madelaine Faulkner , Ahmad, Faraz , McClay, James , Azar, Kristen , Rakotz, Michael , Pletcher, Mark J , Chamberlain, Alanna M , Faulkner Modrow, Madelaine , Cooper‐DeHoff, Rhonda M. , Fontil, Valy, Carton, Thomas, Todd, Jonathan, O’Brien, Emily C., Shaw, Kathryn M., Smith, Myra, Choi, Sujung, Ford, Daniel, Tecson, Kristen M. , Dennar, Princess E., Wu, Shenghui, Singh, Rajbir, Shay, Christina M., Wozniak, Gregory

Mayo Clinic

Journal of the American Heart Association | October 6, 2021 | Volume: 10 | Issue: 21 | Pages: No page available

10.1161/jaha.121.022224 | PMID 34612048 Get It

Background The National Patient‐Centered Clinical Research Network Blood Pressure Control Laboratory Surveillance System was established to identify opportunities for blood pressure (BP) control improvement and to provide a mechanism for tracking improvement longitudinally. Methods and Results We conducted a serial cross‐sectional study with queries against standardized electronic health record data in the National Patient‐Centered Clinical Research Network (PCORnet) common data model returned by 25 participating US health systems. Queries produced BP control metrics for adults with well‐documented hypertension and a recent encounter at the health system for a series of 1‐year measurement periods for each quarter of available data from January 2017 to March 2020. Aggregate weighted results are presented overall and by race and ethnicity. The most recent measurement period includes data from 1 737 995 patients, and 11 956 509 patient‐years were included in the trend analysis. Overall, 15% were Black, 52% women, and 28% had diabetes. BP control (<140/90 mm Hg) was observed in 62% (range, 44%–74%) but varied by race and ethnicity, with the lowest BP control among Black patients at 57% (odds ratio, 0.79; 95% CI, 0.66–0.94). A new class of antihypertensive medication (medication intensification) was prescribed in just 12% (range, 0.6%–25%) of patient visits where BP was uncontrolled. However, when medication intensification occurred, there was a large decrease in systolic BP (≈15 mm Hg; range, 5–18 mm Hg). Conclusions Major opportunities exist for improving BP control and reducing disparities, especially through consistent medication intensification when BP is uncontrolled. These data demonstrate substantial room for improvement and opportunities to close health equity gaps.